-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Nautilus Biotechnology (NASDAQ:NAUT) Shares Down 10.3%
Nautilus Biotechnology (NASDAQ:NAUT) Shares Down 10.3%
Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Get Rating) fell 10.3% during trading on Tuesday . The stock traded as low as $1.55 and last traded at $1.66. 120,820 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 267,068 shares. The stock had previously closed at $1.85.
Nautilus Biotechnology Trading Down 10.3 %
The firm has a market capitalization of $207.04 million, a P/E ratio of -3.39 and a beta of 0.84. The company's fifty day simple moving average is $1.90 and its 200 day simple moving average is $2.29.
Get Nautilus Biotechnology alerts:Institutional Trading of Nautilus Biotechnology
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp grew its position in shares of Nautilus Biotechnology by 11.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 123,683 shares of the company's stock worth $263,000 after buying an additional 12,705 shares during the period. State Street Corp grew its position in shares of Nautilus Biotechnology by 12.4% in the 3rd quarter. State Street Corp now owns 652,325 shares of the company's stock worth $1,383,000 after buying an additional 72,142 shares during the period. Prelude Capital Management LLC purchased a new stake in shares of Nautilus Biotechnology in the 3rd quarter worth about $37,000. Citadel Advisors LLC grew its position in shares of Nautilus Biotechnology by 82.0% in the 3rd quarter. Citadel Advisors LLC now owns 63,062 shares of the company's stock worth $134,000 after buying an additional 28,412 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Nautilus Biotechnology by 40.1% in the 3rd quarter. Renaissance Technologies LLC now owns 89,100 shares of the company's stock worth $189,000 after buying an additional 25,500 shares during the period. 45.25% of the stock is owned by hedge funds and other institutional investors.
About Nautilus Biotechnology
(Get Rating)Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
See Also
- Get a free copy of the StockNews.com research report on Nautilus Biotechnology (NAUT)
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
- The Institutions Choose CarMax Over Carvana, Should You?
- Heatmap in Trading: How to Learn What Market Depth Hides
- Micron Technology Sees Chip Recovery by the End of 2023
- Three Healthcare Penny Stocks to Watch In The New Year
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Get Rating) fell 10.3% during trading on Tuesday . The stock traded as low as $1.55 and last traded at $1.66. 120,820 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 267,068 shares. The stock had previously closed at $1.85.
鸚鵡螺生物科技公司(納斯達克代碼:NAUT-GET評級)週二在交易中下跌10.3%。該股交易價格低至1.55美元,最後報1.66美元。午盤成交量為120,820股,較267,068股的平均成交量下降55%。該股此前收盤價為1.85美元。
Nautilus Biotechnology Trading Down 10.3 %
鸚鵡螺生物技術公司股價下跌10.3%
The firm has a market capitalization of $207.04 million, a P/E ratio of -3.39 and a beta of 0.84. The company's fifty day simple moving average is $1.90 and its 200 day simple moving average is $2.29.
該公司市值為2.0704億美元,本益比為-3.39,貝塔係數為0.84。該公司的50日簡單移動均線切入位為1.90美元,200日簡單移動均線切入位為2.29美元。
Institutional Trading of Nautilus Biotechnology
鸚鵡螺屬生物技術的制度性交易
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp grew its position in shares of Nautilus Biotechnology by 11.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 123,683 shares of the company's stock worth $263,000 after buying an additional 12,705 shares during the period. State Street Corp grew its position in shares of Nautilus Biotechnology by 12.4% in the 3rd quarter. State Street Corp now owns 652,325 shares of the company's stock worth $1,383,000 after buying an additional 72,142 shares during the period. Prelude Capital Management LLC purchased a new stake in shares of Nautilus Biotechnology in the 3rd quarter worth about $37,000. Citadel Advisors LLC grew its position in shares of Nautilus Biotechnology by 82.0% in the 3rd quarter. Citadel Advisors LLC now owns 63,062 shares of the company's stock worth $134,000 after buying an additional 28,412 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Nautilus Biotechnology by 40.1% in the 3rd quarter. Renaissance Technologies LLC now owns 89,100 shares of the company's stock worth $189,000 after buying an additional 25,500 shares during the period. 45.25% of the stock is owned by hedge funds and other institutional investors.
一些對沖基金和其他機構投資者最近調整了對該公司的持股。紐約梅隆銀行(Bank Of New York Mellon Corp)在第三季度將其在Nautilus Biotech的股票頭寸增加了11.4%。紐約梅隆銀行(Bank Of New York Mellon Corp)目前持有123,683股該公司股票,價值263,000美元,在此期間又購買了12,705股。道富集團在第三季度將其在鸚鵡螺生物科技公司的股票頭寸增加了12.4%。道富銀行目前持有652,325股該公司股票,價值1,383,000美元,在此期間又購買了72,142股。Prelude Capital Management LLC在第三季度購買了價值約3.7萬美元的鸚鵡螺生物技術公司的新股份。Citadel Advisors LLC在第三季度將其在鸚鵡螺生物技術公司的股票頭寸增加了82.0%。Citadel Advisors LLC現在擁有63,062股該公司股票,價值13.4萬美元,在此期間又購買了28,412股。最後,復興科技有限責任公司在第三季度將其在鸚鵡螺生物技術公司的股票頭寸增加了40.1%。復興科技有限責任公司現在擁有89,100股該公司股票,價值18.9萬美元,在此期間又購買了25,500股。45.25%的股票由對沖基金和其他機構投資者持有。
About Nautilus Biotechnology
關於鸚鵡螺生物技術
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
鸚鵡螺生物技術公司是一家處於發展階段的生命科學公司,致力於創建一種量化和解鎖蛋白質組複雜性的平臺技術。它開發了Nautilus Platform,這是一個蛋白質組學平臺,包括由儀器、消耗品和軟體分析組成的端到端解決方案。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Nautilus Biotechnology (NAUT)
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
- The Institutions Choose CarMax Over Carvana, Should You?
- Heatmap in Trading: How to Learn What Market Depth Hides
- Micron Technology Sees Chip Recovery by the End of 2023
- Three Healthcare Penny Stocks to Watch In The New Year
- 免費獲取StockNews.com關於鸚鵡螺生物技術的研究報告(Naut)
- 幫助你建立2023年觀察名單的3只工業股票
- 這些機構選擇CarMax而不是Carvana,你應該這樣做嗎?
- 交易熱圖:如何瞭解隱藏的市場深度
- 美光科技預計2023年底晶片回收
- 新年值得關注的三隻醫療保健便士股
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《鸚鵡螺生物技術日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Nautilus Biotech和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧